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Aflibercept is an inhibitor of vascular endothelial growth factor (VEGF) used to treat macular edema following branch retinal vein
occlusion (BRVO). Despite well-documented efficacy, there is limited knowledge about proteome changes following aflibercept
intervention in BRVO. Proteome changes may provide insights into mechanisms of action as well as aspects related to safety
profile. In seven Danish Landrace pigs, BRVO was induced with a well-established experimental model of argon laser-induced
BRVO. BRVO was induced in both eyes. )ree days after the induced BRVO, aflibercept was injected intravitreally in the right
eyes, while the left eyes received intravitreal isotonic saline water. Retinas were collected 15 days after the induced BRVO and
analyzed with label-free quantification liquid chromatography tandem mass spectrometry (LFQ LC-MS/MS). Fourteen proteins
were changed in expression following aflibercept intervention in the BRVOmodel. LFQ LC-MS/MS identified an upregulation of
DnaJ homolog subfamily C member 17 (DNAJC17) (fold change� 6.19) and a modest downregulation of isoform 2 of the protein
encoded by N-myc downstream regulated gene 2 (NDRG2) (fold change� 0.40). NDRG2 was unchanged byWestern blotting. In
the additional significantly regulated proteins, only discrete changes were observed (fold changes 0.52–1.59). Our study is the first
to report an association between aflibercept intervention and the heat shock protein DNAJC17. Our results indicate that the role of
heat shock proteins in the treatment of BRVO should be further explored.
1. Introduction
Branch retinal vein occlusion (BRVO) is the most frequent
retinal vascular disease after diabetic retinopathy [1]. Oc-
clusion of a retinal branch vein is known to cause retinal
non-perfusion, retinal ischemia, and hypoxia, resulting in
the release of vascular endothelial growth factor (VEGF)
[2, 3]. Increased VEGF levels result in breakdown of the
blood-retinal barrier leading to increased vascular perme-
ability and formation of macular edema [1, 2, 4, 5]. Macular
edema is a vision-limiting complication to BRVO which is
effectively treated with intravitreal injections of VEGF in-
hibitors including bevacizumab, ranibizumab, and afli-
bercept [4, 6–9]. By neutralizing VEGF, anti-VEGF agents
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reduce retinal vascular permeability, leading to absorption of
macular edema [4].
Bevacizumab is a monoclonal immunoglobulin G an-
tibody and ranibizumab is a monoclonal antibody fragment
(Fab) derived from bevacizumab. Bevacizumab and rani-
bizumab bind and neutralize all isoforms of VEGF-A [10].
Aflibercept is a fusion protein that contains the second
immunoglobulin domain of VEGF receptor-1 (VEGFR-1)
and the third immunoglobulin domain of VEGF receptor-2
(VEGFR-2) which are fused to the constant Fc domain of
human immunoglobulin G1 [2, 11]. Aflibercept binds all
isoforms of VEGF-A, VEGF-B, and placental growth factor
[2, 11]. Using immunoprecipitation with aflibercept and
retinal pigment epithelium (RPE) cell extracts, Kanda et al.
[12] found that aflibercept also binds galectin-1 and sup-
presses galectin-1 mediated activation of VEGFR-2.
While novel mechanisms of action following aflibercept
intervention have been discovered with immunoprecipita-
tion, retinal proteome changes following aflibercept inter-
vention in BRVO remain unstudied [13]. )erefore, the
effect of aflibercept on retinal large-scale protein changes in
BRVO remains largely unelucidated. )e main objective of
proteome studies is to study the entire set of proteins in a
cell, tissue, or biofluid providing in depth information of
how the given biological system works [13, 14]. Studying
retinal proteome changes following aflibercept intervention
may elucidate novel signaling pathways regulated by afli-
bercept and bring insights into novel mechanisms of action.
Large-scale protein changes are important to uncover, for
therapeutic, and also for safety reasons [13].
Protein changes in some ophthalmological conditions
are best studied in appropriate animal models [15–17].
Animal models are almost always required to obtain retinal
tissue exposed to BRVO [13]. Experimental BRVO may be
induced with diathermia probes as well as argon laser
[16, 18]. Experimental BRVO is effectively induced with
diathermia probes, but this is an invasive approach which
may potentially result in intraocular inflammation as well as
changes in the proteome of the vitreoretinal interface
[16, 18]. Laser-induced BRVO may be performed with or
without an intravenous dye, for example, Rose Bengal. Rose
Bengal facilitates induction of BRVO by absorbing the argon
laser, but radiation of Rose Bengal may result in protein
modifications such as conformational changes, oxidation of
side chains, and unfolding [19].
For proteome studies, intravenous dye and invasive
models with diathermia probes are best avoided. In the
present study we tested aflibercept in a dye-free noninvasive
porcine experimental model of argon laser-induced BRVO.
)e model results in classical findings observed in human
BRVO such as flame-shaped hemorrhages, impaired
drainage from the occluded vein, and breakdown of the
blood-retinal barrier [16, 20–24]. )e porcine eye is well-
suited for studies of retinal vascular diseases, as the porcine
retina is fully vascularized similar to the human retina [25].
Our previous studies have demonstrated that argon laser-
induced experimental BRVO is a robust method in which
BRVO does not re-canalize. )e model is well suited for
proteomic studies and can be used for relevant interventions
including intravitreal anti-VEGF agents and dexamethasone
implants [20, 21, 23]. We have previously tested ranibizu-
mab, bevacizumab, and a dexamethasone implant on the
model [20, 21, 24].
By combining the experimental BRVO model with ad-
vanced proteomic techniques, we provide insights into
retinal proteome changes following aflibercept intervention
in experimental BRVO.
2. Materials and Methods
)e study was approved by the Danish Animal Experiments
Inspectorate, permission no. 2019-15-0201-01651. )e ex-
periments were conducted in accordance with the guidelines
published by the Institute for Laboratory Animal Research
and in adherence to the ARVO Statement for the Use of
Animals in Ophthalmic Research and Vision Research.
Animals were housed under a 12 h light/dark cycle. An-
esthesia, topical anesthesia with eye drops, and dilation of
the pupils were performed as previously described [22].
2.1. Experimental Branch Retinal Vein Occlusion (BRVO) and
Aflibercept Intervention. Experimental BRVO was induced in
seven Danish Landrace pigs by using a well-established ex-
perimental model [16, 20, 21, 23, 24]. In both eyes, BRVO was
induced close to the optic nerve head with a standard argon
laser (532nm), given by indirect ophthalmoscopy using a 20D
lens.)e laser energy was set to 400mWwith an exposure time
of 550ms. A total of 30–40 laser applications were used per
occlusion. Experimental BRVOwas considered successful when
stagnation of venous blood and development of flame-shaped
hemorrhages were observed. Interventions were performed
three days after BRVO. Prior to interventions, both eyes were
treated with povidone iodine eye drops (Skanderborg Phar-
macy, Skanderborg, Denmark). Right eyes were then given an
intravitreal injection of 0.05mL aflibercept 40mg/mL (Bayer,
Leverkusen, Germany). Left eyes received an injection of
0.05mL sodium chloride 9mg/mL (NaCl) (B. Braun, Freder-
iksberg, Denmark). Following the injections, chloramphenicol
ointment 1% (Takeda Pharma A/S, Taastrup, Denmark) was
applied in both eyes. Fluorescein angiography was performed 5
days after BRVOwas induced. Fifteen days after BRVO, the eyes
were enucleated and immediately dissected on ice under a
microscope. )e anterior segment was removed by cutting
3.5mm posteriorly to the limbus. )e vitreous body was gently
aspired into a 5mL syringe.)e neurosensory retina was peeled
with tweezers from the RPE/choroid and stored at −80°C. )e
reproducibility of the BRVO model at the molecular level was
tested in six additional Danish Landrace pigs. In these animals,
BRVO (n� 6) was induced in the right eyes as described above.
In the left eyes which served as controls (n� 6), identical laser
burns were created with the same number of applications and
laser energy as used in the right eyes without creating a BRVO.
BRVOwas confirmed with fluorescein angiography, and retinal
samples were collected and stored as described above.
2.2. Sample Preparation for Mass Spectrometry. Samples
intended for proteomic analysis by mass spectrometry were
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stored at −80°C until sample preparation for label-free
tandem mass spectrometry was initiated. Eyes from six
animals were used to compare the protein profile of
BRVO+ aflibercept (n� 6) vs. BRVO+NaCl (n� 6). )e
reproducibility of the BRVOmodel was tested by comparing
BRVO (n� 6) and controls (laser only) (n� 6) with pro-
teomic analysis.
Frozen samples were mixed with a lysis buffer consisting
of 5% sodium deoxycholate (SDC) and 20mM triethyl
ammonium bicarbonate (TEAB) in a tissue-to-buffer ratio of
approximately 1 : 20 (approximately 300 µL). )e samples
were sonicated on ice with a Sonicator Q125 (QSonica LLC)
with the following settings: amplitude 75%, three sonications
for 59 seconds with 59-second rest between sonication runs.
)e samples were then incubated in a heating block with
agitation (600 rpm) at 99°C for 5min and were then allowed
to chill slowly to room temperature. )e extracts were
centrifuged at 16, 000g for 10min, and supernatants were
transferred to new 2mL tubes.
)e protein concentration of each sample was measured
by infrared spectrometry using a Direct Detect Spectrometer
(Merck KGaA, Darmstadt), as described in a recent article
[26]. A volume of 5 µL 200mM tris 2-carboxyethyl phos-
phine (TCEP) and 20mM TEAB solution was added to a
100 µL sample, followed by incubation at 55°C for 1 h. Five
µL of freshly prepared 375mM iodoacetamide was added to
each sample followed by incubation for 30min, at room
temperature while being protected from light. )e lysates
were added to filter units (Microcon Centrifugal Filter
Devices 30K fromMillipore) and centrifuged at 14,000g for
15min. A volume of 100 µL of digestion buffer (0.5% SDC,
20mMTEAB) was added to the filter unit and centrifuged at
14,000g for 15min. )is step was performed twice. After-
wards, 2.5 µg trypsin was added to each sample, followed by
mixing at 600 rpm in a thermomixer for 1min. )e filter
units were incubated overnight at 37°C. Filter units were
transferred to new collection tubes and centrifuged at
14,000g for 10min. Another two centrifugation runs were
performed with 100 µL digestion buffer. An equal volume of
ethyl acetate was added followed by addition of 10% tri-
fluoroacetic acid (TFA) to a final concentration of 0.5% (vol/
vol) of the final volume obtained after washing with di-
gestion buffer. )e samples were then shaken for 1min, and
centrifuged for 2min at max speed, 14,000 rpm. )e upper
phase was removed and the lower phase was saved. Similar
volumes of ethyl acetate were added two additional times,
each time shaken, centrifuged, and finally removed. )e
samples were dried in a vacuum centrifuge, resuspended in
100mMTEAB, and the peptide concentration wasmeasured
by fluorescence as previously described [24].
2.3. Quantitative Mass Spectrometry by Label-Free Quanti-
tative Nanoliquid Chromatography Tandem Mass Spec-
trometry (LFQ LC-MS/MS). Label-free quantification by
nanoliquid chromatography tandem mass spectrometry was
performed on an Orbitrap Fusion Tribrid mass spectrometer
()ermo Fisher Scientific Instruments, Waltham, MA, USA)
coupled to a Dionex UltiMateTM 3000 RSLC nano system.
)e instrument was equipped with an EasySpray™ ion
source. Peptide separation by liquid chromatography was
performed as previously described [24], with a few modi-
fications. )e analytical columns were 750mm
(750mm× 75 µm PepMap RSCL, C18, 2 µm, 100 Å, )ermo
Scientific) and a 4h gradient was made by mixing buffer A
(99.9% water, 0.1% formic acid) with buffer B (99.9% ace-
tonitrile, 0.1% formic acid). Mass spectrometry was per-
formed with the Universal Method for label-free
quantification. Two µg of each sample was injected. Full
scans were obtained in the Orbitrap at a scan range of
400–1500m/z and a resolution of 120,000. Further settings
included an automatic gain control target of 4×105 and a
maximum injection time of 50ms. Precursor ions were
isolated in the quadrupole. A collision-induced dissociation
energy of 35% was applied. MS2 scans were detected in the
ion trap with automatic gain control target of 2×103 and a
maximum injection time of 300ms.
With MaxQuant software version 1.6.3.4 [27], raw data
files generated from LFQ LC-MS/MS were searched against
the Uniprot Sus scrofa database and the Uniprot Homo
sapiens database as described in a previous work [24].
Unfiltered results from the database search are available in
Appendix A.
2.4. Statistics. Mass spectrometry data was processed further
with Perseus software version 1.6.2.3 [28] to remove poorly
identified proteins as described in a previous article [22].
LFQ values were log2-transformed. Technical replicates
were averaged. For successful protein identification, at least
two unique peptides were required. Additionally, proteins
were required to be successfully identified and quantified in
at least 70% in each of the two groups compared. All proteins
that were successfully identified and quantified are available
in Appendix B. Statistical analysis by Student’s t-test was
performed in Perseus and proteins were considered statis-
tically significantly regulated if p< 0.01. Volcano plots were
created in STATA 16.0 (StataCorp, College Station, TX,
USA) by plotting −log(p value) against log2-transformed
LFQ abundance ratios.
2.5. Western Blotting. Western blotting was performed as
previously described [22], with the exception that protein
concentrations were adjusted by adding 5% SDC with 20mM
TEAB and that expression of the protein under validation was
normalized using a polyclonal rabbit anti-beta tubulin anti-
body 1 : 500 (AB6046, Abcam, Cambridge, UK). NDRG2 was
quantified with a polyclonal rabbit antibody directed at
NDRG2 1 : 500 (MBS8207067, MyBioSource, San Diego, CA,
USA). Statistical analysis was performed by Student’s t-test on
log-transformed densitometric data.
2.6. Immunohistochemistry. Eyes from one animal were
used to compare BRVO+ aflibercept (n� 1) with
BRVO+NaCl (n� 1). Immunohistochemistry was per-
formed as previously described [24]. Briefly, retinal samples
were fixated in a fixative of 99% ethanol (three parts) and
Journal of Ophthalmology 3
glacial acetic acid (one part) for 5 h and stored in a 0.1M
phosphate buffer solution at 4°C until further use. Immu-
nohistochemistry was performed with the same anti-
NDRG2 antibody as described above for Western blotting
(AB8069, Abcam, Cambridge, UK). For immunohisto-
chemistry, the antibodies were diluted in PBS + 0.3% Triton
X100 reaching a dilution of 1 : 500. Retinal sections were
incubated overnight at 4°C and processed with EnVision
DakoCytomation DAB.
3. Results
3.1. Evaluation of Experimental Branch Retinal Vein
Occlusion. Experimental BRVO was successfully induced
based on development of venous dilation and flame-shaped
hemorrhages (Figure 1(a)). Fluorescein angiography per-
formed five days after BRVO showed no recanalization of
the occluded veins in any of the animals (Figure 1(b)).
Proteomic analysis by mass spectrometry confirmed a
good reproducibility of the BRVO model at the molecular
level. Protein changes in the BRVO model were consistent
with protein changes that were previously observed in the
model (Appendix C) [23].
3.2. Proteome Changes following Aflibercept Intervention.
High contents of aflibercept components were observed in
retinas treated with the compound. )e VEGFR-1 immu-
noglobulin domain of aflibercept was only identified and
quantified in retinas treated with aflibercept. )e VEGFR-1
immunoglobulin domain was identified as UniProtID
P17948. A high content of the VEGFR-2 immunoglobulin
domain of aflibercept was observed in retinas treated with
aflibercept (fold change� 64.64; p value� 0.000016) (Uni-
ProtID P35968) (Table 1).
Fourteen proteins were statistically significantly changed
following aflibercept intervention in BRVO (Table 1) (Fig-
ure 2). An upregulation of DnaJ homolog subfamily C
member 17 (DNAJC17) was identified following aflibercept
intervention in BRVO (fold change� 6.19; p � 0.0011). A
slight downregulation of isoform 2 of the protein of N-myc
downstream regulated gene 2 (NDRG2) following afli-
bercept intervention was observed with LFQ LC-MS/MS
(fold change� 0.40; p � 0.00070). )e modest down-
regulation of NDRG2 was not confirmed with Western
blotting (fold change� 1.17; p � 0.73) (Figure 3). Immu-
nohistochemistry revealed some decreased staining for
NDRG2 following aflibercept intervention in BRVO
(Figures 4(a) and 4(b)).
Decreased staining for NDRG2 was observed in the
nerve fiber layer, the ganglion cell layer, and the inner
nuclear layer. In the additional proteins that were regulated
following aflibercept intervention, fold changes ranged from
0.52 to 1.59 (Table 1) (Figure 2).
4. Discussion
4.1. Experimental Model of Branch Retinal Vein Occlusion.
)ere are a number of models of experimental BRVO that
are available for research purposes [18, 29]. )e argon laser-
induced BRVO model used in our study is well-suited for
proteomic studies as the model is noninvasive [16, 20, 23].
Alternatively, invasive models with, for example, diathermia
probes may affect the proteome of the vitreoretinal interface
which renders invasive models less suitable for proteomic
studies [16].
Full occlusion of a retinal branch vein may be difficult to
achieve in experimental BRVO models and recanalization
may be a problem [16, 29]. In the presented study, we
demonstrated that recanalization did not occur in the BRVO
model.
In most cases, BRVO occurs at sites of arteriovenous
crossing where the retinal vein is compressed by a retinal
artery that has thickened due to years of hypertension and
arteriosclerosis [1, 30]. Compression of a retinal vein by an
arteriosclerotic artery is not possible to induce in animal
models of BRVO [13, 29]. With no underlying arterioscle-
rotic disease, pigs have a faster recovery from BRVO than
humans [23]. )e time frame of 14 days following experi-
mental BRVO is considered suitable for the study of BRVO
and interventions, as the model translates well into findings
observed in human BRVO within this period [21, 23].
Previous reports have shown that anti-VEGF injections
can have some effect in the untreated fellow eye [31, 32].
However, results from our previous studies of the BRVO
model have indicated that anti-VEGF agents reach high
retinal concentrations with high concentration differences
between treated and nontreated eyes [20, 21]. )erefore, the
fellow eye was considered suitable as a control.
4.2. Aflibercept Intervention in Experimental BRVO. High
retinal contents of VEGFR-1 and VEGFR-2 immunoglob-
ulin domains of aflibercept were measured in retinas treated
with aflibercept.)us, our data indicates that very high levels
of aflibercept are reached within 14 days of treatment. Only
14 proteins were statistically significantly changed in content
following aflibercept intervention. Based on our proteomic
data, we did not find that aflibercept regulated multiple
proteins in the BRVO model. In terms of safety profile, it
may be an important observation that aflibercept did not
cause changes in multiple signaling pathways that may have
unwanted side effects. Unlike intravitreal dexamethasone
[24], aflibercept did not regulate a broad spectrum of
proteins indicating that dexamethasone implants have a
wider mechanism of action than aflibercept. Knowledge
about the spectrum of proteins regulated by aflibercept is
important when making decisions about adequate therapy.
)e proteins with largest regulations included DNAJC17
and possibly NDRG2. DNAJC17 is a heat shock protein
family member known to be involved in splicing-related
processes [33], but the function of DNAJC17 remains largely
unknown [33]. DNAJC17 belongs to a class of cofactors
called J-proteins. J-proteins are cofactors of 70 kilodalton
heat shock proteins (Hsp70s). )e so-called J-domain of the
J-proteins stimulates ATPase activity of Hsp70s. Mutations
in the DNAJC17 gene have been reported to be associated
with retinitis pigmentosa and hypogammaglobulinemia
[34]. A mutation in the DNAJC17 gene has also been
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described in patients with essential thrombocytopenia [35].
To the best of our knowledge, our study is the first to describe
an association between aflibercept intervention and
DNAJC17. Further investigation is needed in order to es-
tablish the role of DNAJC17 in the treatment of BRVO.
Immunohistochemistry showed slightly reduced stain-
ing for NDRG2 in the nerve fiber layer, the ganglion cell
layer, and the inner nuclear layer following aflibercept in-
tervention. As the change in NDRG2 was small, Western
blotting may not have been sufficiently sensitive to confirm
the regulation of NDRG2. NDRG2 belongs to the family
proteins encoded by N-Myc downstream-regulated genes
(NDRGs) and is expressed in many cellular compartments
including cytoplasm, cell membrane, and nuclei [36].
NDRG2 is markedly upregulated in hypoxic conditions
[37, 38]. )ere is only limited knowledge about the role of
retinal NDRG2 and further studies are required to determine
if retinal NDRG2 is a hypoxia sensitive protein in BRVO.
Changes in the additional significantly regulated pro-
teins were small, ranging within fold changes of 0.52–1.59.
Changes in content were minimal in most of the proteins.
Moderate changes in content were observed in Bcl-2-like
protein 13 (fold change� 1.59), inosine-5-monophosphate
dehydrogenase 2 (fold change� 1.52), 5-3 exoribonuclease 2
(fold change� 1.47), and MICOS complex subunit MIC60
(MICOS) (fold change� 0.52). Bcl-2-like protein 13 is
known to be associated with removal of damaged mito-
chondria [39]. Inosine-5-monophosphate dehydrogenase 2
BRVO day 0
(a)
Fluorescein angiography day 3
(b)
Figure 1: Experimental branch retinal vein occlusion (BRVO). (a) Fundus image of BRVO taken approximately 10minutes after BRVOwas
induced in the inferior retina. Black arrow: site of occlusion. White arrow: dilated vein upstream of occlusion. (b) Validation of BRVO by
fluorescein angiography five days after BRVO. No passage of fluorescein through the occluded vein is observed. Shunting to adjacent veins is
observed. White arrow: site of occlusion.
Table 1: Proteins which were regulated following aflibercept intervention in experimental BRVO.
Protein ID Protein name p value Fold change
P35968 Vascular endothelial growth factor receptor 2 (aflibercept) 0.000016 64.64
Q9NVM6 DnaJ homolog subfamily C member 17 0.0011 6.19
Q9BXK5-2 Isoform 1 of Bcl-2-like protein 13 0.0075 1.59
P12268 Inosine-5-monophosphate dehydrogenase 2 0.0070 1.52
Q9H0D6-2 Isoform 2 of 5-3 exoribonuclease 2 0.0082 1.47
Q9UPQ0-10 Isoform 10 of LIM and calponin homology domains-containing protein 1 0.0070 1.37
Q8WZA9 Immunity-related GTPase family Q protein 0.0022 1.36
P63208-2 Isoform 2 of S-phase kinase-associated protein 1 0.0086 1.35
Q6Q7J2 Rab GDP dissociation inhibitor beta 0.0041 0.86
P62191 26S proteasome regulatory subunit 4 subunit 4 0.0098 0.71
P20585 DNA mismatch repair protein Msh3 0.0077 0.66
Q29195 60S ribosomal protein L10 0.0088 0.61
Q16891-3 Isoform 3 of MICOS complex subunit MIC60 0.0053 0.52
Q9UN36-2 Isoform 2 of protein NDRG2 0.00070 0.40
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Figure 2: Volcano plot. Quantitative data from label-free quantification liquid chromatography tandem mass spectrometry (LFQ LC-MS/
MS) were measured as label-free quantification (LFQ) values. Log2 LFQ ratios (aflibercept/NaCl) are plotted on the x-axis. On the y-axis,
−log p value refers to the logarithmized p value from the t-test used to test if a protein was significantly regulated. )e black horizontal line









































Figure 3: Proteomic analysis by mass spectrometry revealed a downregulation of NDRG2 in the BRVO model following aflibercept
intervention. However, the downregulation of NDRG2 was not sufficiently large to be confirmed with Western blotting (p � 0.73).
6 Journal of Ophthalmology
is involved in de novo synthesis of guanine nucleotides and a
regulator of cell growth [40]. 5-3 exoribonuclease 2 is a
promoter of RNA polymerase II transcription [41]. MICOS
complex subunit MIC60 is a component of the mitochon-
drial contact site and cristae organizing system (MICOS)
complex.)eMICOS complex is involved inmaintenance of
mitochondrial structure, lipid metabolism, and protein
import [42].
In our previous bevacizumab study, we identified an
increased retinal content of transthyretin following bev-
acizumab intervention in the BRVO model [20]. In the
present aflibercept study, we identified an increased level of
transthyretin following aflibercept intervention, but the
upregulation was not statistically significant (p � 0.15; fold
change� 2.34). Other proteins that were regulated by bev-
acizumab were not identified with mass spectrometry in the
present study.
5. Conclusions
With advanced proteomics techniques, we aimed at iden-
tifying large-scale retinal protein changes following afli-
bercept intervention in experimental BRVO. Overall, very
few proteins were regulated following aflibercept interven-
tion, and modest changes were observed in most of the
regulated proteins. Our study identified an upregulation of
the heat shock protein DNAJC17 following aflibercept in-
tervention in experimental BRVO. To the best of our
knowledge, an association between DNAJC17 and afli-
bercept intervention has not previously been described.
Further studies will be required to shed light on the function
of retinal DNAJC17, and a potential association with VEGF.
Our findings also indicate that the role of heat shock proteins
in BRVO warrants further study. A downregulation of
NDRG2 was observed in experimental BRVO treated with
aflibercept. Further studies are necessary to uncover the
biological role of retinal NDRG2. Based on our proteomic
data, aflibercept did not regulate multiple signaling path-
ways. In terms of safety profile, it is a relevant observation
that aflibercept did not cause changes in multiple signaling
pathways that may have unwanted side effects. In retinas
treated with aflibercept, high retinal levels of VEGFR-1 and
VEGFR-2 immunoglobulin domains of aflibercept were
observed indicating that a high aflibercept concentration was
reached within 14 days of aflibercept treatment.
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cluded within the supplementary materials.
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Figure 4: (a) and (b), immunohistochemistry showed a slight downregulation of NDRG2 in the retinal ganglion cell layer and the inner
nuclear layer following aflibercept intervention in BRVO. Scale bar� 31 µm. Reaction color: brown. ILM: inner limiting membrane; NFL:
nerve fiber layer; GCL: ganglion cell layer; IPL: inner plexiform layer; INL: inner nuclear layer; OPL: outer plexiform layer; ONL: outer
nuclear layer; IS: inner segment; OS: outer segment.
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Appendix A: unfiltered results from database search. Ap-
pendix B: all successfully identified and quantified proteins.
Appendix C: test of reproducibility of the BRVO model at
the molecular level. (Supplementary Materials)
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